Board of Directors 

The Board of Directors is the legally and financially responsible body that sets the strategic direction of TOPRA and makes sure that all is running smoothly. Board elections are held annually for Officers and every two years for Directors. Any member, wherever they live or whatever their regulatory experience, can stand for election.

TOPRA's president for 2024, Michael Kipping, lays out his plans for presidency at the 2023 TOPRA Symposium.

The members of the Board in 2024 are:

Office	Term	Name	Career summary
President	1 year	Michael Kipping MTOPRA	Michael is Director, Medical Technologies EMEAA for Element Materials Testing, which is a global testing, inspection, calibration and certification business. Previously, he worked for Innovate UK as a Health Innovation Lead managing a UK government grant funding programme (Biomedical Catalyst) that provided £30M per annum to support UK SMEs developing innovative health and life science products.
President-Elect	1 year	Aman Khera FTOPRA	Aman is Vice President, Regulatory Science, Strategy & Innovation at Worldwide Clinical Trials, a global  contract research organisation (CRO). Aman provides global strategic direction in regulatory affairs, having led a wide range of regulatory projects providing strategy and development services for a variety of client sponsor companies.
Past-President	1 year	Áine Kane MTOPRA	Áine Kane is a Senior Director in the Global Chemistry, Manufacturing, And Controls (CMC) team at Pfizer, UK and has worked as a CMC regulatory professional for the past 17 years. She currently supports global regulatory submissions across the product lifecycle for biological products and manages a team of colleagues based in Ireland and the US.

Directors

Office	Term	Name and professional position	Career summary
Director	2 years	Eva Kopecna FTOPRA	Eva works for Acino International as Global Head of Regulatory Affairs, Medical and Pharmacovigilance. She has over 35 years combined experience of healthcare and pharmaceutical industry in a range of positions. After spending 12 years as a medical doctor, Eva moved to research and development, and later regulatory affairs where she has built and lead different teams.
Director	2 years	Steve Lee FTOPRA	Steve joined ABHI as Director of Diagnostics Regulation in 2020. After completing his degree in Biochemistry and Biology at Aston University, Steve trained as a Biomedical Scientist, working in hospital microbiology before moving to industry to work as company microbiologist. In 2019, Steve was presented with the TOPRA Award for Regulatory Excellence for Contribution.
Director	2 Years	Abbie Lennox MTOPRA	Abbie is Executive Board Member and Chief Regulatory, Medical, Safety & Product Compliance Officer at Bayer Consumer Health and leads end-to-end regulatory, medical affairs, safety, research and development, quality and product compliance. With over 20 years’ experience in regulatory affairs, she believes in the science of selfcare to empower people to transform their everyday health.
Director	2 years	Sonja Morjaria MTOPRA	Sonja has over 15 years’ experience in regulatory affairs and is currently the Associate Director of Regulatory Strategy UK&IE at Vertex Pharmaceuticals. Sonja leads the development of strategies for assets early in the pipeline, through to post marketing for cell and gene therapy products. She has been a TOPRA member since the start of her career and completed her MSc through TOPRA’s programme.
Director	2 years	Abishek Sinha MTOPRA	Abhishek is Global Director for Regulatory Affairs at ADVANZ PHARMA, a global pharmaceutical company committed to improving patients’ lives by providing and enhancing the specialty, hospital and rare disease medicines. He has over 20 years’ experience in regulatory affairs, having led international teams while supporting research and development pipelines.
Director	2 years	Alex Yates FTOPRA	Alex has been working in Regulatory Affairs since 2002, and is currently Vice President Regulatory Affairs at BicycleTx Ltd (Bicycle). Alex is responsible for the development and execution of the global regulatory strategy for the company’s portfolio. He is also responsible for the development of the global regulatory team, associated supporting systems and infrastructure.

Our 2024 Board co-optees are: